SCHEMBL22976016

SCHEMBL22976016

NCCCCCCNCCCCC(N)C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.74
GNAI3 P08754 1/20 0.53
GNAO1 P09471 1/20 0.53
GNAI1 P63096 1/20 0.53
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
ARG2 P78540 4/20 0.47
ARG1 P05089 3/20 0.47
CA12 O43570 1/20 0.46
F13A1 P00488 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CYP1A2 P05177 1/20 0.46
CA3 P07451 1/20 0.46
CYP2C9 P11712 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21131222 1.00 GSR (0.74) GSRGNAI3GNAO1GNAI1MAOA
SCHEMBL19965187 1.00 GSR (0.74) GSRGNAI3GNAO1GNAI1MAOA
Hydrochloric Acid SCHEMBL19953118 0.98 GSR (0.71) GSRGNAI3GNAO1GNAI1MAOA
Hydrochloric Acid SCHEMBL19953117 0.98 GSR (0.71) GSRGNAI3GNAO1GNAI1MAOA
SCHEMBL448753 0.98 GSR (0.77) GSRGNAI3GNAO1GNAI1MAOA
SCHEMBL6757882 0.98 GSR (0.77) GSRGNAI3GNAO1GNAI1MAOA
SCHEMBL19952912 0.96 GSR (0.68) GSRGNAI3GNAO1GNAI1MAOA
SCHEMBL19952845 0.96 GSR (0.68) GSRGNAI3GNAO1GNAI1MAOA
SCHEMBL19952914 0.96 GSR (0.68) GSRGNAI3GNAO1GNAI1MAOA
SCHEMBL19952847 0.96 GSR (0.68) GSRGNAI3GNAO1GNAI1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3509575-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE UNIV TEMPLE (US) 2025-03-19 EP claimed
US-11596615-B2 Compositions and methods for treatment of insulin resistance Temple University—Of the Commonwealth System of Higher Education (US) 2023-03-07 US claimed
US-20210046030-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-02-18 US claimed
US-20210052532-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-02-25 US disclosed
CN-112088006-A Compositions and methods for treating insulin resistance 坦普尔大学 2020-12-15 CN disclosed
CN-110139644-A For treating the composition and method of insulin resistance 坦普尔大学 2019-08-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052532-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE GPR119, FABP4, SLC2A3 GSR 88/4885GNAI3 2791/4885GNAO1 4489/4885
US-11596615-B2 Compositions and methods for treatment of insulin resistance GPR119, INSR, IAPP GSR 185/4885GNAI3 2623/4885GNAO1 3016/4885
US-20210046030-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE GPR119, INSR, IAPP GSR 185/4885GNAI3 2623/4885GNAO1 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.